NEW YORK, Nov. 11 (GenomeWeb News) - Promega has filed a motion with the US District Court of Delaware seeking an injunction to stop Benitec from granting further licenses to ddRNAi technology to which it claims exclusivity.
The motion is the latest move in row between the two companies over rights to the RNAi technology. In July, Benitec sued Promega, which had acquired the exclusive rights to use and sublicense the ddRNAi technology in areas outside human therapeutics in exchange for $350,000 and royalties.
The suit claims that Promega had failed to meet its payment requirements to Benitec, and therefore had forfeited its exclusive rights to the technology in lieu of a non-exclusive license to simply use the technology.
Promega's motion follows Benitec's announcment in October that it had granted Artemis Pharmaceuticals of